Garner is a behavioral intervention scientist and an assistant professor of nutritional sciences.

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS ...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...

The company hopes to list its shares on Nasdaq under the symbol AAPG. Lead bookrunners ... Ascentage (AAPG) hopes to file for FDA approval of the product in 2026.

Attendees of the $349 “ Don’t Die Summit ” at the west side’s Javits Center tried red light therapy, discovered their ...

Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an ...

Next up: The FDA is going to work on a symbol that foods can use that have the healthy claim approved for them. It should make it easier for you to identify what’s really good for you.

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

Those shares will trade on the Nasdaq under the stock symbol “AAPG.” The only commercialized Ascentage product is olverembatinib, a drug approved ... to support an FDA new drug application ...